Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) Meeting
Cellular, Tissue and Gene Therapies Advisory Committee · July 30, 2026
Advisory committee heard FDA reviewers and Replimmune present conflicting interpretations of IGNITE trial data for RP‑1 (visolimogene) plus nivolumab in PD‑1‑refractory advanced cutaneous melanoma; patients urged approval; committee voted that the evidence was evaluable and clinically meaningful (10–3).
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.